{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:12:55Z","timestamp":1788887575178,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:sec>\n            <jats:title>Backgrounds:<\/jats:title>\n            <jats:p>Baricitinib, an oral selective inhibitor of Janus kinase 1 and 2, is approved for moderate and severe rheumatoid arthritis (RA) with insufficient response to conventional synthetic disease-modifying antirheumatic drugs. The study evaluated the safety of baricitinib 24 weeks 4\u2009mg or 2\u2009mg for the treatment of RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The net change (least squares mean [LSM]) of alanine aminotransferase (ALT), creatinine, low-density lipoprotein cholesterol (LDL-C) levels from baseline with the comparison of baricitinib versus placebo was pooled, respectively. The risk ratios (RR) of serious advanced events (SAEs), major cardiovascular events (MACEs), infection, serious infection, and advanced events (AEs) at the end of treatment across groups were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Five randomized controlled trials with 2901 patients were included in the summary analysis. Results showed that baricitinib 4\u2009mg significantly increased ALT and creatinine levels, the net LSM change was respectively 3.59 U\/L with 95% confidence interval (CI) (1.75\u20135.43), 4.25 \u00b5mol\/L with 95% CI (3.38\u20135.12), however, baricitinib 2\u2009mg of ALT and creatinine levels were not significantly different. Baricitinib 4\u2009mg and 2\u2009mg significantly increased LDL-C levels, the net LSM change was respectively 11.44\u2009mg\/dL with 95% CI (6.08\u201316.80), 8.70\u2009mg\/dL with 95% CI (4.19\u201313.20). Baricitinib 4\u2009mg significantly increased the incidence of infection, the pooled RR (95% CI) was 1.29 (1.13\u20131.47), and baricitinib 2\u2009mg was not significantly different. However, the pooled RRs of SAEs, MACEs, and serious infection were not statistically significant across groups. The pooled RRs of AEs were not statistically significant between baricitinib 4\u2009mg and 2\u2009mg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study confirmed that patients with RA taking 4\u2009mg baricitinib increased levels of ALT, creatinine, as well as an increased risk of infections, compared with those taking 2\u2009mg baricitinib. Both 2\u2009mg and 4\u2009mg also increased the level of LDL-C, but it increased the most severely at 4\u2009mg baricitinib. However, the incidence of SAEs, MACEs, and serious infection was not significantly different in patients treated with baricitinib 4\u2009mg and 2\u2009mg compared with placebo, the incidence of AEs was not significantly different between baricitinib 4\u2009mg and 2\u2009mg.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040512","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:00:00Z","timestamp":1732032000000},"page":"e40512","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Safety of baricitinib 24 weeks 4\u2009mg or 2\u2009mg for the treatment of rheumatoid arthritis: A meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"103","author":[{"given":"Zhihua","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Hunan University of Medicine General Hospital, Huaihua, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hunan University of Medicine General Hospital, Huaihua, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hunan University of Medicine General Hospital, Huaihua, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hunan University of Medicine General Hospital, Huaihua, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2233-6539","authenticated-orcid":false,"given":"Lang","family":"She","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hunan University of Medicine General Hospital, Huaihua, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mcna.2020.10.006","article-title":"Rheumatoid arthritis: early diagnosis and treatment.","volume":"105","author":"Cush","year":"2021","journal-title":"Med Clin North Am"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","article-title":"Rheumatoid arthritis: advances in treatment strategies.","volume":"478","author":"Prasad","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future.","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1759720X16687481","article-title":"Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.","volume":"9","author":"Kuriya","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"First global approval.","volume":"77","author":"Baricitinib","year":"2017","journal-title":"Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib. A Review in Rheumatoid Arthritis.","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"R7-20250504","first-page":"460","article-title":"FDA approves Eli Lilly\u2019s baricitinib.","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease modifying antirheumatic drug treatment.","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250504","first-page":"1","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.","volume":"0","author":"Dougados","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis.","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis.","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20250504","first-page":"732","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.","volume":"38","author":"Li","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers.","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA approved JAK inhibitor for the treatment of rheumatoid arthritis.","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann Pharmacother"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","article-title":"Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a metaanalysis of randomized controlled trials.","volume":"18","author":"Qiu","year":"2019","journal-title":"Lipids Health Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk.","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:03:23Z","timestamp":1746320603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":20,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040512","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}